Adlai Nortye Ltd. (ANL)

12.73 -1.26 (-9.01%) At close: 04:00PM EDT

Adlai Nortye Ltd.

Ugland House
PO Box 309
Grand Cayman KY1-1104
Cayman Islands
848 230 7430
https://www.adlainortye.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 127

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Yang Lu	CEO & Chairman	N/A	N/A	1981
Ms. Wei Zhang	Chief Financial Officer	N/A	N/A	1992
Dr. Kaiyang Tang	Senior VP & Global Head of Clinical Operations	N/A	N/A	1965
Dr. Victoria Elizabeth Demby Ph.D.	Senior VP & Global Head of Regulatory Affairs	N/A	N/A	1971
Dr. Ngai Chiu Tse M.D., Ph.D.	Head of Research & Development	N/A	N/A	1968

Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas. The company is also developing AN0025, a small molecule prostaglandin E receptor 4 antagonist to modulate the tumor microenvironment that is in a Phase Ib clinical trial for the treatment of recurrent non-small cell lung cancer and urothelial cancer after anti-PD-1/PD-L1 treatments, recurrent triple-negative breast cancer, microsatellite stable colorectal cancer, and cervical cancer after standard of care treatments; and AN4005, an oral small-molecule PD-L1 inhibitor, which is in Phase I clinical trial to induce and stabilize PD-L1 dimerization and thereby disrupt the interaction between PD-1 and PD-L1. Its preclinical candidates include AN8025, a multifunctional antibody as T cell and antigen-presenting cell modulator; AN1025, an oral small molecule degrader of ß-catenin; and AN9025, an oral small molecule pan-KRAS inhibitor. The company was founded in 2004 and is based in Grand Cayman, the Cayman Islands.

Corporate governance

Adlai Nortye Ltd.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.